Compare EPC & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPC | SLS |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.9M | 924.5M |
| IPO Year | 1999 | 2007 |
| Metric | EPC | SLS |
|---|---|---|
| Price | $23.33 | $7.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $23.33 | $10.00 |
| AVG Volume (30 Days) | 828.6K | ★ 9.9M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,223,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.64 | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.73 | $1.39 |
| 52 Week High | $27.24 | $9.51 |
| Indicator | EPC | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 72.94 | 54.17 |
| Support Level | $18.92 | $3.72 |
| Resistance Level | $24.21 | $9.51 |
| Average True Range (ATR) | 0.91 | 0.75 |
| MACD | 0.67 | -0.21 |
| Stochastic Oscillator | 96.47 | 35.86 |
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Wet Shave products include razor handles and refillable blades, disposable shave products, and shaving gels and creams. Sun and Skin Care consists of sun care products, men's and women's grooming products, Billie women's grooming products and personal wipe products. Feminine Care products include tampons, pads and liners. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.